Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696308 | 0.82 | ALDH1A1 (0.36) | HSD17B10ALDH1A1GAAHTTMAPT | |
| SCHEMBL22641030 | 0.80 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4ECYP1A2KMT2A | |
| Acetic Acid SCHEMBL28203964 | 0.73 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL10507092 | 0.71 | ALDH1A1 (0.47) | SMN1; SMN2HSD17B10ALDH1A1GAAPOLB | |
| SCHEMBL22135199 | 0.68 | ALDH1A1 (0.35) | SMN1; SMN2KDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL14152308 | 0.67 | CYP1A2 (0.37) | SMN1; SMN2KDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL2871580 | 0.65 | — | — | |
| SCHEMBL6115483 | 0.64 | KDM4E (0.35) | SMN1; SMN2KDM4EHSD17B10POLBCYP1A2 | |
| SCHEMBL26766993 | 0.64 | ALDH1A1 (0.45) | SMN1; SMN2KDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL13924818 | 0.64 | CSNK2A2 (0.42) | HSD17B10ALDH1A1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | claimed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | claimed |
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | SMN1; SMN2 2358/4885KDM4E 1770/4885HSD17B10 4777/4885 |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | SMN1; SMN2 2282/4885KDM4E 3497/4885HSD17B10 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.